Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Trastornos del Movimiento
FILTRAR POR:
Por tema
4562 ARTÍCULOS , VIENDO DEL 2971 AL 2985
Agreement between clinician-rated versus patient-reported outcomes in Huntington disease
Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai JS, Dayalu P.
J Neurol. 2018 Jun;265(6):1443-1453. doi: 10.1007/s00415-018-8852-5. Epub 2018 Apr 23.
Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease
Loi SM, Walterfang M, Velakoulis D, Looi JC.
Australas Psychiatry. 2018 Aug;26(4):376-380. doi: 10.1177/1039856218766120. Epub 2018 Apr 24.
Rab GTPases and Membrane Trafficking in Neurodegeneration
Kiral FR, Kohrs FE, Jin EJ, Hiesinger PR.
Curr Biol. 2018 Apr 23;28(8):R471-R486. doi: 10.1016/j.cub.2018.02.010.
Retinal dysfunction in a presymptomatic patient with Huntington's disease
Knapp J, VanNasdale DA, Ramsey K, Racine J.
Doc Ophthalmol. 2018 Jun;136(3):213-221. doi: 10.1007/s10633-018-9632-3. Epub 2018 Apr 24.
The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review
Yaribeygi H, Panahi Y, Javadi B, Sahebkar A.
CNS Neurol Disord Drug Targets. 2018;17(3):207-215. doi: 10.2174/1871527317666180425122557.
Age-related neuropathies and tubulin acetylation
Fernández-Barrera J, Correas I, Alonso MA.
Aging (Albany NY). 2018 Apr 28;10(4):524-525. doi: 10.18632/aging.101432.
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease
Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.
Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1.
Rosas-Arellano A, Estrada-Mondragón A, Mantellero CA, Tejeda-Guzmán C, Castro MA.
Neural Regen Res. 2018 Apr;13(4):584-590. doi: 10.4103/1673-5374.230270.
Autophagy in Age-Associated Neurodegeneration
Metaxakis A, Ploumi C, Tavernarakis N.
Cells. 2018 May 5;7(5):37. doi: 10.3390/cells7050037.
Inherited and Acquired Choreas
de Gusmao CM, Waugh JL.
Semin Pediatr Neurol. 2018 Apr;25:42-53. doi: 10.1016/j.spen.2018.01.002. Epub 2018 Feb 23.
Movement Disorders and Neurometabolic Diseases
Christensen CK, Walsh L.
Semin Pediatr Neurol. 2018 Apr;25:82-91. doi: 10.1016/j.spen.2018.02.003. Epub 2018 Feb 14.
Huntington's disease: Current and future therapeutic prospects
Kieburtz K, Reilmann R, Olanow CW.
Mov Disord. 2018 Jul;33(7):1033-1041. doi: 10.1002/mds.27363. Epub 2018 May 8.
Ameliorating the age at onset and disease progression in Huntington disease
Morrison PJ, Delatycki MB.
Neurology. 2018 Jun 12;90(24):1087-1088. doi: 10.1212/WNL.0000000000005670. Epub 2018 May 9.
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães F, Pinto M, Sousa E.
Pharmaceuticals (Basel). 2018 May 11;11(2):44. doi: 10.3390/ph11020044.
Spontaneous Intracranial Hypotension as a Cause of Exacerbation in Huntington's Disease
Figueroa EL, Jog MS, Pelz DM, Lownie SP.
Can J Neurol Sci. 2018 May;45(3):357-359. doi: 10.1017/cjn.2017.296.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.